Navigation Links
Encision Reports Second Quarter of Fiscal Year 2013 Results
Date:10/30/2012

BOULDER, Colo., Oct. 30, 2012 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 second quarter ended September 30, 2012. 

The Company posted quarterly product revenue of $2.806 million and quarterly service revenue of $68 thousand for a quarterly net loss of $265 thousand, or $(0.03) per share. These results compare to product revenue of $2.830 million and service revenue of $437 thousand for a net loss of $469 thousand, or $(0.07) per share, in the year-ago quarter. Gross margin was 56 percent compared to 48 percent in the year-ago quarter. In the year-ago quarter, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product. Also, the gross profit margin increase from the second quarter of fiscal year 2012 was due, partially, to an increase in gross margin of our disposable scissor inserts.

The Company posted six months product revenue of $5.611 million and six months service revenue of $364 thousand for a six months net loss of $254 thousand, or $(0.03) per share. These results compare to product revenue of $5.664 million and service revenue of $787 thousand for a net loss of $490 thousand, or $(0.04) per share, in the year-ago six months. Gross margin was 56 percent compared to 52 percent in the year-ago six months. In the year-ago six months, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product.

"Although we were disappointed that we did not have product revenue growth for the second quarter, we made significant strides to position the company for future growth," said Fred Perner, President and CEO. "We had expected the decrease in service revenue. In our last quarter's earnings release we announced that, as a result of a project that was phased out by a strategic partner, and unless we obtained another strategic partner or further commitments from existing partners, we anticipated that future service revenue would be significantly reduced as compared to last fiscal year's service revenue."

"We continued to use financial resources that were obtained from the issuance of our common stock for sales, marketing, quality programs and product development initiatives to grow future revenue and profitability. During the quarter, in order to obtain broader sales coverage, we changed the composition of our sales management and regions. Also, we introduced quality enhancements to our product line, including an improved disposable foot-activated fixed-tip electrode and an enhanced disposable scissor, the e-Edge™ Scissor, which we began shipping in mid-September. Both of these products are pivotal to our recurring revenue strategy."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2012 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:
Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

 Encision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited) September 30, 2012March 31, 2012ASSETSCash and cash equivalents$
558$
565Accounts receivable, net1,0851,428Inventories, net2,4722,489Prepaid expenses10728Total current assets4,2224,510Equipment, net1,6541,619Patents, net276273Other assets77Total assets$ 6,159$ 6,409LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$   728$ 1,040Accrued compensation284283Other accrued liabilities407349Total current liabilities1,4191,672Common stock and additional paid-in capital21,55421,297Accumulated (deficit)(16,814)(16,560)Total shareholders' equity4,7404,737Total liabilities and shareholders' equity$ 6,159$  6,409 Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited) Three Months EndedSix Months EndedSeptember 30, 2012September 30, 2011September 30, 2012September 30, 2011Net revenue:Product$ 2,806$ 2,830$5,611$ 5,664Service68437364787Total revenue2,8743,2675,9756,451Cost of revenue:Product1,2021,5252,4062,786Service60176208320Total cost of revenue1,2621,7012,6143,106Gross profit1,6121,5663,3613,345Operating expenses:Sales and marketing9451,2131,8122,250General and administrative452463980882Research and development478342820673Total operating expenses1,8752,0183,6123,805Operating loss(263)(452)(252)(460)Interest and other expense, net(2)(17)(2)(30)Loss before provision for income taxes(265)(469)(254)(490)Provision for income taxes––––––––Net loss$  (265)$  (469)$
(254)$  (490)Net loss per share—basic and diluted$ (0.03)$ (0.07)$   (0.03)$ (0.04)Basic and diluted weighted average number of shares8,2106,4558,1896,455
'/>"/>

SOURCE Encision Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports First Quarter of Fiscal Year 2013 Results
2. Luminex Corporation Reports Third Quarter 2012 Results
3. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
4. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
5. Global Collaboration Effective in Dismantling Rogue Online Prescription Drug Sellers, Reports NABP
6. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
7. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2012
8. Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
9. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
10. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
11. China Botanic Reports Third Quarter Fiscal Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):